noscript

News and Announcements

Biotech Acquires Bioatrix

  • Published January 14, 2016 9:15AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

In December 2015, US company ZZ Biotech LLC completed the acquisition of Bioatrix Pty Ltd. Based in Houston, ZZ Biotech is in a Phase 2 trial with 3K3A-Activated Protein C (‘3K3A-APC’) in acute ischemic stroke patients, supported by a grant from the National Institute for Neurological Disease and Stroke.  ZZ Biotech’s Australian subsidiary is presently manufacturing 3K3A-APC at Patheon Biologics in Brisbane and it has secured Queensland Government grant funding to facilitate the manufacture.  The Australian subsidiary will pursue a Phase 2 trial with 3K3A-APC in chronic wounds in 2016, and ZZ Biotech will undertake further trials of 3K3A-APC in stroke.

 

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now